Status: question. Rule: atlas-profile-2.0.
5 linked publications; not a count of independent studies.
Missing appraisal does not mean no evidence exists. Inspect the full profile and source relationships in the interactive Atlas.
Historical grade: UNRESOLVED-CONTROVERSY (retained from 22 September 2026; not a completed profile 2.0 assessment).
This is the single most common unresolved daily decision in neuro-oncology; current practice defaults to watchful waiting, delaying effective therapy or prolonging toxic ineffective therapy.
Cohort-level separation exists (perfusion, PET) but thresholds do not transfer across sites; RANO 2.0 still relies on confirmation scans.
Prospective multi-vendor cohort with biopsy/long-follow-up ground truth, pre-registered thresholds, calibration + decision-curve analysis; amino-acid PET arm where available.
This question comes from selected literature. Confirm that the gap remains open with a current search and mentor review.
This is an educational research resource from Resonant Labs, not clinical advice. Atlas assessments are heuristic, not probabilities or formal GRADE ratings. Findings are summarized from the literature and may change as the field evolves.